Annual report pursuant to Section 13 and 15(d)

REVENUES (Tables)

v3.22.0.1
REVENUES (Tables)
12 Months Ended
Dec. 31, 2021
REVENUES  
Schedule of revenues disaggregated by category

Revenues disaggregated by category were as follows (in thousands):

​

​

​

​

​

​

​

​

​

​

​

​

Year Ended December 31,

​

​

2021

    

2020

    

2019

Product sales:

​

​

​

​

​

​

​

​

​

Gross product sales

​

$

81,186

​

$

76,470

​

$

53,082

Discounts and allowances

​

​

(18,176)

 

​

(14,774)

 

​

(9,310)

Total product sales, net

​

​

63,010

​

​

61,696

​

​

43,772

Revenues from collaborations:

​

​

​

​

​

​

​

​

​

License revenues

​

​

70,553

​

​

40,358

​

​

8,696

Development milestones

​

​

1,875

 

​

2,100

 

​

5,500

Research and development services and others

​

​

3,298

 

​

4,467

 

​

1,320

Total revenues from collaborations

​

​

75,726

​

​

46,925

​

​

15,516

Government contract

​

​

10,500

​

​

—

​

​

—

Total revenues

​

$

149,236

​

$

108,621

​

$

59,288

Schedule of product revenue allowance and reserve categories

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Chargebacks,

​

Government

​

​

​

​

​

​

Discounts and

​

and Other

​

​

​

​

​

​

Fees

​

Rebates

​

Returns

​

Total

Balance as of January 1, 2021

    

$

2,461

 

$

2,115

​

$

1,489

​

$

6,065

Provision related to current period sales

​

​

10,731

​

​

5,036

​

​

1,021

​

​

16,788

Credit or payments made during the period

​

​

(9,788)

​

​

(4,657)

​

​

(493)

​

​

(14,938)

Balance as of December 31, 2021

 

$

3,404

​

$

2,494

​

$

2,017

​

$

7,915

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Chargebacks,

​

Government

​

​

​

​

​

​

​

​

Discounts and

​

and Other

​

​

​

​

​

​

​

​

Fees

​

Rebates

​

Returns

​

Total

Balance as of January 1, 2020

    

$

1,293

 

$

1,801

​

$

238

​

$

3,332

Provision related to current period sales

​

​

8,149

​

​

4,231

​

​

950

​

​

13,330

Adjustment related to prior period sales

​

​

(75)

​

​

(490)

​

​

565

​

​

—

Credit or payments made during the period

​

​

(6,906)

​

​

(3,427)

​

​

(264)

​

​

(10,597)

Balance as of December 31, 2020

 

$

2,461

​

$

2,115

​

$

1,489

​

$

6,065

Schedule of revenues from product sales disaggregated by customers

The following table summarizes revenues from each of our customers who individually accounted for 10% or more (wherein * denotes less than 10%) of the total net product sales and revenues from collaborations:

​

​

​

​

​

​

​

​

​

​

​

Year Ended December 31,

​

2021

    

2020

​

2019

Lilly

​

48%

​

​

—

​

​

—

McKesson Specialty Care Distribution Corporation

​

20%

​

​

23%

​

​

30%

ASD Healthcare and Oncology Supply

​

17%

​

​

30%

​

​

37%

Grifols

​

*

​

​

41%

​

​

*